Analysis of Revenues
Paying user area
Try for free
IQVIA Holdings Inc. pages available for free this week:
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Operating Profit Margin since 2013
- Current Ratio since 2013
- Total Asset Turnover since 2013
- Price to Book Value (P/BV) since 2013
- Price to Sales (P/S) since 2013
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to IQVIA Holdings Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
IQVIA Holdings Inc., income statement, revenues
US$ in millions
| 12 months ended: | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Technology & Analytics Solutions | |||||||||||
| Research & Development Solutions | |||||||||||
| Contract Sales & Medical Solutions | |||||||||||
| Revenues |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
The analyzed data presents revenue figures across several business segments over a five-year period. The overall revenue demonstrates a consistent upward trend, indicating growth in the company's total sales.
- Technology & Analytics Solutions
- This segment shows steady growth year-over-year from 2018 to 2022. Revenue increased from 4,137 million USD in 2018 to 5,746 million USD in 2022. The growth rate accelerated particularly after 2020, signaling increased market demand or successful expansion initiatives in this area.
- Research & Development Solutions
- This category also exhibits overall growth, starting at 5,465 million USD in 2018 and reaching 7,921 million USD in 2022. A notable rise occurred between 2020 and 2021, where revenue jumped sharply by nearly 31%, suggesting significant scaling or increased contracts in this division. The rate of increase continued but slowed down between 2021 and 2022.
- Contract Sales & Medical Solutions
- This segment follows a relatively flat trend, with revenue fluctuating but overall showing a slight decline from 810 million USD in 2018 to 743 million USD in 2022. The dip is most evident after 2019, reflecting either decreased demand or strategic shifts away from this unit.
- Overall Revenues
- The company's total revenue shows a consistent upward trajectory, increasing from 10,412 million USD in 2018 to 14,410 million USD in 2022. The most significant annual increase occurred between 2020 and 2021, with a 22% rise, likely driven by strong performances in the Technology & Analytics Solutions and Research & Development Solutions segments. Growth continued into 2022 but at a more moderate pace.
In summary, the data reflects sustained revenue growth primarily fueled by the Technology & Analytics Solutions and Research & Development Solutions segments, while the Contract Sales & Medical Solutions segment displays a stable yet slightly declining contribution. The overall upward revenue trend suggests effective market positioning and expansion in high-growth areas.